Log in
Enquire now
Lexeo Therapeutics

Lexeo Therapeutics

Lexeo Therapeutics is a gene Therapy founded in 2018 by Ronald Crystal.

OverviewStructured DataIssuesContributors

Contents

lexeotx.com
Is a
Investor
Investor
Organization
Organization
Company
Company
Venture capital firm
Venture capital firm

Company attributes

Industry
Tissue engineering
Tissue engineering
Healthcare
Healthcare
Regenerative medicine
Regenerative medicine
‌
Rare disease
Biotechnology
Biotechnology
Biology
Biology
Biomedical engineering
Biomedical engineering
...
Location
New York City
New York City
0
New York
New York
CEO
‌
R. Nolan Townsend
0
Founder
‌
Ronald Crystal
0
Pitchbook URL
pitchbook.com/profiles...455072-77
Number of Employees (Ranges)
11 – 50
Email Address
Phone Number
Number of Employees
410
Full Address
430 East 29th Street, 14th Floor, New York, US
345 Park Avenue South, 6th Floor New York, NY 100100
Investors
PBM Capital
PBM Capital
Janus Henderson
Janus Henderson
Lundbeckfonden Ventures
Lundbeckfonden Ventures
Woodline Partners
Woodline Partners
Alexandria Venture Investments
Alexandria Venture Investments
Omega Funds
Omega Funds
Longitude Capital
Longitude Capital
...
Founded Date
2018
Total Funding Amount (USD)
85,000,000
Latest Funding Round Date
January 2021
Latest Funding Type
Series A
Series A
Country
United States
United States
0

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
85,000,000
Public/Private
Private
No article content yet.

Timeline

No Timeline data yet.

Associated Investment Funds

Accelerator Batches

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Lexeo Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Become an Editor
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.